Catalog No.S2487 Synonyms: Mycophenolate, RS-61443
Molecular Weight(MW): 320.34
Mycophenolic acid is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.
Purity & Quality Control
Choose Selective Dehydrogenase Inhibitors
|Description||Mycophenolic acid is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug, used to prevent rejection in organ transplantation.|
Mycophenolic acid inhibits inosine-5'-monophosphate dehydrogenase (IMPDH) by acting as a replacement for the nicotinamide portion of the nicotinamide adenine dinucleotide cofactor and a catalytic water molecule.  Mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase, in nanomolar concentrations blocks proliferative responses of cultured human, mouse and rat T lymphocytes and B lymphocytes to mitogens or in mixed lymphocyte reactions. Mycophenolic acid (MPA) suppresses mixed lymphocyte reactions when added 3 days after their initiation. Mycophenolic acid also inhibits antibody formation by polyclonally activated human B lymphocytes. Mycophenolic acid is an immunosuppressive agent reversibly inhibiting proliferation of T and B lymphocytes and antibody formation, with a profile of activity different from that of other immunosuppressive drugs.  Mycophenolic acid inhibits the formation of antibodies to sheep erythrocytes. Mycophenolic acid also suppresses, in a dose-related manner, the generation of cytotoxic T-lymphocytes against allogeneic cells in mice and prevents the elimination of allogeneic cells.  Mycophenolic acid induces apoptosis and cell death in a large proportion of activated CD4+ T cells. 
|In vivo||Mycophenolic acid has lymphocyte-selective anti-proliferative effects in mice and can inhibit both cell-mediated and humoral immune responses without major side effects. |
|In vitro||DMSO||64 mg/mL (199.78 mM)|
|Ethanol||5 mg/mL (15.6 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01503242||Recruiting||Plasma Cell Myeloma|Refractory Plasma Cell Myeloma||Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)||January 9, 2012||Phase 1|
|NCT02782546||Recruiting||Acute Myeloid Leukemia||Washington University School of Medicine||January 30, 2017||Phase 2|
|NCT02423915||Recruiting||Leukemia|Lymphoma||M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas||July 30, 2015||Phase 1|Phase 2|
|NCT00425802||Completed||Leukemia|Lymphoma||Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)||November 28, 2006||Phase 2|
|NCT01701986||Recruiting||Lymphoma||M.D. Anderson Cancer Center||October 25, 2012||Phase 1|Phase 2|
|NCT00723099||Suspended||Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Indolent Non-Hodgkin Lymphoma|Malignant Lymphoma, Large Cell Type|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Chronic Lymphocytic Leukemia|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Follicular Lymphoma|Refractory Hodgkin Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Non-Hodgkin Lymphoma||Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)||June 25, 2008||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.